Access Consortium Promise Pilot Pathway
The Access Consortium working group for new active substances has established an aligned process for priority review, which includes the decision on priority status. In order to facilitate the process for applicants, common timelines for the priority review request have been established, and the request is evaluated in a collaborative way, seeking a consensus decision.
Read the news story from Medicines and Healthcare products Regulatory Agency published on 15 December 2023.
OpenEdition vous propose de citer ce billet de la manière suivante :
lsgilbert (13 février 2024). Access Consortium Promise Pilot Pathway. ELSIBI. Consulté le 16 janvier 2025 à l’adresse https://doi.org/10.58079/vtrj
